BPC-157 FDA status in 2026: Category 2 removal and the advisory vote

Three events define where BPC-157 stands. The table gives the dates and the practical effect of each, and the sections below expand on them. The short version is that the compound has moved from "flagged as a safety concern" to "under active consideration for compounding", which is a real shift in direction and no shift at all in what you can legally buy.

The FDA sorts substances nominated for compounding under section 503A into categories while it evaluates them. Category 1 substances may be compounded under enforcement discretion while review continues. Category 2 is for substances the agency has identified as presenting significant safety risks, and pharmacies are not supposed to touch them. In late 2023 the FDA put BPC-157 in Category 2 alongside several other popular peptides, including CJC-1295 and ipamorelin.

The stated reasoning was the kind of gap the compound page describes: no completed human trials, no established safety profile, unknown immunogenicity, and a mechanism involving angiogenesis that raises theoretical tumor concerns. For clinics that had been prescribing compounded BPC-157, the placement cut off their supply overnight. It did nothing to research vendors, who were never part of the compounding system, which is why availability barely changed for most buyers.

In April 2026 the FDA removed BPC-157 and eleven other peptides from Category 2. The move was widely reported as the FDA "unbanning" BPC-157, and that is the wrong reading. Removal from Category 2 means the agency no longer classifies the substance as presenting significant safety risks on the available evidence. It does not place the substance in Category 1, so pharmacies gain no interim permission to compound it. It simply moves the compound back into the queue for a proper evaluation. The removal followed HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement of an intent to move roughly 14 of the 19 Category 2 peptides back toward Category 1, which was a statement of intent rather than a rule.

The distinction matters because enforcement discretion for Category 1 is what lets compounding pharmacies work with a substance before a final rule exists. Without that, a pharmacy compounding BPC-157 in May 2026 was in the same legal position as one doing it in 2024. The glossary entry on the Category 2 list covers the framework in more detail.

On July 23 and 24, 2026 the FDA's Pharmacy Compounding Advisory Committee considered seven nominated peptides and recommended six of them for the list of bulk drug substances that may be used in compounding under section 503A: BPC-157, KPV and TB-500 by 8 to 6 with one abstention each, MOTS-c by 7 to 5 with two abstentions, Semax by 8 to 5 for cerebral ischemia, migraine and trigeminal neuralgia, and Epitalon by 7 to 5 with one abstention for insomnia. It rejected the seventh, emideltide (DSIP), by a single vote. FDA career scientists had recommended against adding any of the seven. The committee weighs the evidence of safety and effectiveness, historical use, and whether a clinical need exists that approved drugs do not meet, and an 8 to 6 split on BPC-157 signals a committee that found the rodent data persuasive on mechanism and the human data thin, which is a fair summary of the literature.

Advisory committee votes are recommendations. The FDA usually follows them but is not required to, and the next step is formal rulemaking: a proposed rule, a public comment period, and a final rule. Past additions to the 503A list have generally taken many months, often more than a year, to move from a vote to a final rule, and the agency is also working through its GLP-1 compounding proposal at the same time. As of October 2026 no final rule for BPC-157 has been reported.

What the vote does signal is that the FDA now has an on-record expert recommendation in favor of legitimate compounding, which changes the conversation for clinics and compounding pharmacies planning for 2027. It changes nothing for the compound's status as a drug.

The advisory vote concerned the 503A list only. A 503A pharmacy compounds a patient-specific preparation from an individual prescription, and is overseen mostly by state boards of pharmacy. A 503B outsourcing facility can produce larger batches without a named patient, registers with the FDA, and follows manufacturing standards closer to those of a drug maker. The two sections have separate bulk substance lists with separate criteria.

If BPC-157 is eventually added to the 503A list, the result would be a clinician writing a prescription for a named patient and a compounding pharmacy filling it. It would not mean 503B batch production, over the counter sale, or anything resembling the current research market. The 503B question would be a separate nomination with a higher bar, since 503B listing requires a demonstrated clinical need, and the FDA's 2026 proposal to pull the GLP-1 drugs off that list shows how narrowly it reads that requirement.

Approval and compounding eligibility are different tracks. Approval requires a sponsor to run phase 1 through phase 3 trials, submit a new drug application, and pass manufacturing inspection. Nobody has done that for BPC-157. The compound was characterized in the early 1990s, a few early phase trials for inflammatory bowel disease and one small intra-articular knee study were run, and none were followed by the large controlled trials approval needs. Its patents are old, which weakens the commercial case for a sponsor to spend the money.

That is why the compound page rates human trials as pilot level and safety data as limited, and why the honest framing remains that nearly all the evidence is rodent work from a single research group. Compounding eligibility, if it comes, would be the FDA accepting that pharmacists can prepare it on prescription. It would not be the FDA saying it works.

BPC-157 is prohibited under section S0 of the WADA Prohibited List, which covers non-approved substances with no current approval for human therapeutic use by any government health authority. Nothing the FDA did in 2026 moves it out of that section, since neither Category 2 removal nor 503A listing is an approval. Tested athletes should assume it remains banned in and out of competition. The same applies to TB-500, which is named explicitly on the list, and to the whole growth hormone secretagogue class.

Practically, nothing has changed. The only route remains research use vendors, the product remains a reagent with no sterility or dose guarantee, and the burden of checking what is in the vial remains with the buyer. The things that mattered in 2024 still matter: a third party COA with HPLC purity and mass spec identity, a lot number on the vial that matches the certificate, and a vendor with a track record. How to buy peptides and how to read a COA cover both.

The decision that would change things is a final rule adding BPC-157 to the 503A list. That would open a prescription route through compounding pharmacies, with pharmacist oversight, sterility testing and a known concentration on the label. Until it is published, treat any clinic selling compounded BPC-157 in the US with the same scrutiny as any research vendor, and probably more, since the clinic markup buys you a prescription pad rather than a better product.

Reported dosage patterns have not moved either: 250 to 500 mcg once or twice daily remains what appears in community protocols, with injectable use for tendons and oral for gut complaints. The oral versus injectable page covers the routes, and BPC-157 vs TB-500 the usual pairing.